Sex-Related Differences in Pancreatic Ductal Adenocarcinoma Progression and Response to Therapy

被引：0
作者：
Grahovac, Jelena [1 ]
Duric, Ana [1 ]
Tanic, Miljana [1 ]
Krivokuca, Ana [1 ]
机构：
[1] Inst Oncol & Radiol Serbia, Expt Oncol Dept, Pasterova 14, Belgrade 11000, Serbia
来源：
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2024年 / 25卷 / 23期
关键词：
PDAC; sex disparity; tumor immunity; therapy; CANCER RISK; NAB-PACLITAXEL; BODY-SIZE; GENDER; GEMCITABINE; IRINOTECAN; PHARMACOKINETICS; FOLFIRINOX; SURVIVAL; TUMOR;
D O I：
10.3390/ijms252312669
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Pancreatic ductal adenocarcinoma (PDAC) is one of the most deadly malignancies with an increasing incidence rate and limited therapeutic options. Biological sex has an impact on many aspects of PDAC development and response to therapy, yet it is highly unappreciated in both basic and translational research, and worryingly in PDAC clinical trials. In this review, we summarize how biological sex influences PDAC incidence and mortality, genetic and epigenetic landscapes, anti-tumor immunity, responses to hormones, cachexia, and the efficacy of therapy. We highlight the importance of sex as a variable and discuss how to implement it into preclinical and clinical research. These considerations should be of use to researchers aiming at improving understanding of PDAC biology and developing precision medicine therapeutic strategies.
引用
收藏
页数：19
相关论文
共 50 条
  • [41] Sex-related differences in Japanese patients with peripheral arterial disease
    Kumakura, Hisao
    Kanai, Hiroyoshi
    Araki, Yoshihiro
    Kasama, Shu
    Sumino, Hiroyuki
    Ito, Toshio
    Iwasaki, Toshiya
    Takayama, Yoshiaki
    Ichikawa, Shuichi
    Fujita, Kishu
    Nakashima, Kuniki
    Minami, Kazutomo
    ATHEROSCLEROSIS, 2011, 219 (02) : 846 - 850
  • [42] Serum interleukin-6 is associated with pancreatic ductal adenocarcinoma progression pattern
    Kim, Hyoung Woo
    Lee, Jong-chan
    Paik, Kyu-hyun
    Kang, Jingu
    Kim, Jaihwan
    Hwang, Jin-Hyeok
    MEDICINE, 2017, 96 (05)
  • [43] A heads up on concussions: are there sex-related differences?
    Brook, Emily M.
    Luo, Xuan
    Curry, Emily J.
    Matzkin, Elizabeth G.
    PHYSICIAN AND SPORTSMEDICINE, 2016, 44 (01) : 20 - 28
  • [44] Pathologic complete response following neoadjuvant therapy for pancreatic ductal adenocarcinoma: defining the incidence, predictors, and outcomes
    Cloyd, Jordan M.
    Ejaz, Aslam
    Shen, Chengli
    Dillhoff, Mary
    Williams, Terence M.
    Noonan, Anne
    Pawlik, Timothy M.
    Tsung, Allan
    HPB, 2020, 22 (11) : 1569 - 1576
  • [45] Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma
    Ecker, Brett L.
    Tao, Alice J.
    Janssen, Quisette P.
    Walch, Henry S.
    Court, Colin M.
    Balachandran, Vinod P.
    Crane, Christopher H.
    D'Angelica, Michael I.
    Drebin, Jeffrey A.
    Kingham, T. Peter
    Soares, Kevin C.
    Iacobuzio-Donahue, Christine A.
    Vakiani, Efsevia
    Gonen, Mithat
    O'Reilly, Eileen M.
    Varghese, Anna M.
    Jarnagin, William R.
    Wei, Alice C.
    CLINICAL CANCER RESEARCH, 2023, 29 (07) : 1368 - 1374
  • [46] Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis
    Chae, Heejung
    Jeong, Hyehyun
    Cheon, Jaekyung
    Chon, Hong Jae
    Ryu, Hyewon
    Kim, Il-Hwan
    Kang, Myoung Joo
    Jeong, Jae Ho
    Ryoo, Baek-Yeol
    Kim, Kyu-pyo
    Yoo, Changhoon
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [47] KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression
    Zhang, Zining
    Zhang, Heng
    Liao, Xiang
    Tsai, Hsiang-i
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2023, 11
  • [48] Plasminogen deficiency suppresses pancreatic ductal adenocarcinoma disease progression
    Chowdhury, Nayela N.
    Yang, Yi
    Dutta, Ananya
    Luo, Michelle
    Wei, Zimu
    Abrahams, Sara R.
    Revenko, Alexey S.
    Shah, Fenil
    Miles, Lindsey A.
    Parmer, Robert J.
    de Laat, Bas
    Wolberg, Alisa S.
    Luyendyk, James P.
    Fishel, Melissa L.
    Flick, Matthew J.
    MOLECULAR ONCOLOGY, 2024, 18 (01) : 113 - 135
  • [49] DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma
    Ettrich, Thomas J.
    Perkhofer, Lukas
    von Wichert, Goetz
    Gress, Thomas M.
    Michl, Patrick
    Hebart, Holger F.
    Buechner-Steudel, Petra
    Geissler, Michael
    Muche, Rainer
    Danner, Bettina
    Kaechele, Volker
    Berger, Andreas W.
    Guethle, Melanie
    Seufferlein, Thomas
    BMC CANCER, 2016, 16
  • [50] Molecular biology in pancreatic ductal adenocarcinoma: implications for future diagnostics and therapy
    Soreide, Kjetil
    Primavesi, Florian
    Labori, Knut J.
    Watson, Martin M.
    Staettner, Stefan
    EUROPEAN SURGERY-ACTA CHIRURGICA AUSTRIACA, 2019, 51 (03): : 126 - 134
12345